

Wyeth launches China's first infant formula with two types of HMOs

27 March 2024 | News

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months



This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months

Filling a gap in the local HMO market, the recently released illumina HMO Liquid Formula is the first in China to contain two essential HMOs, 2'-Fucosyllactose (2'-FL) and Lacto-N-neotetraose (LNnT). This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months. It diminishes lower respiratory tract infections by 55 per cent, bronchitis by 70 per cent, and the likelihood of using antibiotics by 53 per cent.

Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started. Nestlé Research & Development (China) and Wyeth Nutrition are the project's sponsors. Shanghai Jiao Tong University School of Medicine's Xinhua Hospital is in charge of the endeavour. Collaborating with clinical centres in elite hospitals around the country, the project aims to verify the clinical effectiveness of the two HMOs that have been approved for Chinese infants. This will ensure that more Chinese babies can timely and continuously benefit from the early-life health benefits that HMOs bring.